Clark Perdue is investigating claims of bladder cancer as a result of ingestion of Actos.
Actos ("pioglitazone") is a prescription drug used to improve blood sugar levels in individuals with type II diabetes. Pioglitazone is also available in combination with metformin as ActoplusMet and Competact or in combination with glimepiride as Duetact.
What is the problem with Actos?
On September 17, 2010, the Food and Drug Administration (FDA) issued a Safety Communication as a result of the interim analysis of an ongoing 10 year study regarding Actos and bladder cancer. The interim analysis, done five years into the study, found that the risk of bladder cancer increased as exposure to Actos increased. Less than a year later, on June 15, 2011, the FDA issued an updated Drug Safety Communication reporting the finding that individuals who used Actos for a year or more have a greatly increased risk of developing cancer of the bladder. Other studies have revealed that Actos users have a much higher incidence of bladder cancer than people who use other prescriptions for diabetes. As a result of these studies, both the French Agency for the Safety of Health Products and Germany's Federal Institute for Drugs and Medical Devices have withdrawn Actos from the market in those countries.
Who manufactures Actos?
Actos is manufactured by Takeda Pharmaceutical Co., Japan's biggest drug maker. Actos was the tenth best selling drug in the United States in 2008 with sales in excess of $2.4 billion in that year. From January 2010 through October 2010, approximately 2.3 million people used Actos.
Who has a claim?
Anyone who has taken Actos and been diagnosed with bladder cancer may have a claim. Clark, Perdue & List has substantial experience with pharmaceutical injury claims. If you were prescribed Actos for Type II diabetes, and you have been diagnosed with bladder cancer, you may have claim. Contact the Ohio Actos attorneys at Clark, Perdue & List or call us at 1-866-603-1668 today.
